Campbell & CO Investment Adviser LLC Acquires Shares of 51,490 Integra LifeSciences Holdings Corporation $IART

Campbell & CO Investment Adviser LLC bought a new position in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 51,490 shares of the life sciences company’s stock, valued at approximately $632,000. Campbell & CO Investment Adviser LLC owned approximately 0.07% of Integra LifeSciences at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of IART. Access Investment Management LLC acquired a new position in Integra LifeSciences during the second quarter worth $5,348,000. Wellington Management Group LLP grew its stake in shares of Integra LifeSciences by 10.4% during the 1st quarter. Wellington Management Group LLP now owns 2,766,125 shares of the life sciences company’s stock worth $60,827,000 after purchasing an additional 259,987 shares during the period. Nuveen LLC purchased a new position in shares of Integra LifeSciences in the 1st quarter valued at about $5,118,000. Victory Capital Management Inc. lifted its stake in shares of Integra LifeSciences by 1,067.6% in the first quarter. Victory Capital Management Inc. now owns 147,982 shares of the life sciences company’s stock valued at $3,254,000 after purchasing an additional 135,308 shares during the period. Finally, Alliancebernstein L.P. boosted its holdings in Integra LifeSciences by 5.0% during the first quarter. Alliancebernstein L.P. now owns 2,706,434 shares of the life sciences company’s stock worth $59,514,000 after buying an additional 128,041 shares in the last quarter. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. Wall Street Zen raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. JPMorgan Chase & Co. raised their price objective on Integra LifeSciences from $12.00 to $13.00 and gave the company an “underweight” rating in a research note on Friday, October 31st. Truist Financial reiterated a “hold” rating and set a $13.00 target price (down from $15.00) on shares of Integra LifeSciences in a research report on Monday, November 3rd. Weiss Ratings restated a “sell (e+)” rating on shares of Integra LifeSciences in a research report on Thursday. Finally, Citigroup lowered their price objective on shares of Integra LifeSciences from $12.00 to $11.00 and set a “sell” rating on the stock in a research note on Friday, October 31st. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and four have issued a Sell rating to the stock. Based on data from MarketBeat.com, Integra LifeSciences presently has a consensus rating of “Reduce” and an average target price of $15.83.

Integra LifeSciences Stock Down 2.4%

IART opened at $11.75 on Friday. The firm has a market cap of $915.23 million, a P/E ratio of -1.80 and a beta of 1.20. The business’s fifty day simple moving average is $14.04 and its 200 day simple moving average is $13.53. Integra LifeSciences Holdings Corporation has a 52 week low of $10.87 and a 52 week high of $27.13. The company has a quick ratio of 0.73, a current ratio of 1.23 and a debt-to-equity ratio of 1.18.

Integra LifeSciences (NASDAQ:IART) last released its earnings results on Thursday, October 30th. The life sciences company reported $0.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.43 by $0.11. The company had revenue of $402.06 million for the quarter, compared to analyst estimates of $414.31 million. Integra LifeSciences had a negative net margin of 30.87% and a positive return on equity of 12.15%. The firm’s quarterly revenue was up 5.6% on a year-over-year basis. During the same period in the prior year, the firm earned $0.41 EPS. Integra LifeSciences has set its Q4 2025 guidance at 0.790-0.840 EPS. FY 2025 guidance at 2.190-2.240 EPS. As a group, equities research analysts anticipate that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current fiscal year.

Insider Buying and Selling

In other Integra LifeSciences news, Director Jeffrey A. Graves purchased 9,000 shares of the business’s stock in a transaction on Wednesday, November 5th. The stock was bought at an average cost of $11.35 per share, for a total transaction of $102,150.00. Following the acquisition, the director owned 41,086 shares of the company’s stock, valued at approximately $466,326.10. The trade was a 28.05% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 3.54% of the company’s stock.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.